ena-STUDY-HOSPITAL SIRIO LIBANES-28-09-2020-15:54:56:245-472
RNA sequencing and RIP sequencing of CHLA-01R MSI1 knockdown and control cells
We established that Msi1 is required to maintain cancer relevant phenotypes, stem cell signaling and tumor growth and is implicated in chemo- and radio-resistance. We analyzed the regulatory impact of Msi1 on CHLA-01R Group 4 medulloblastoma. Msi1 knockdown disrupted cancer relevant phenotypes and genomic analyses (RNA-seq and RIP-seq) indicated that cell cycle and division are the main biological categories regulated by Msi1 in Group 4 medulloblastoma. We recently developed an inhibitor against Msi1 (luteolin) that disrupts it RNA binding properties. We showed that luteolin by itself and in combination with vincristine affected the growth of CHLA-01R cells. These findings suggest a combined therapeutic strategy (Msi1 + cell cycle/division inhibitors) to treat groups 4 medulloblastoma.
We established that Msi1 is required to maintain cancer relevant phenotypes, stem cell signaling and tumor growth and is implicated in chemo- and radio-resistance. We analyzed the regulatory impact of Msi1 on CHLA-01R Group 4 medulloblastoma. Msi1 knockdown disrupted cancer relevant phenotypes and genomic analyses (RNA-seq and RIP-seq) indicated that cell cycle and division are the main biological categories regulated by Msi1 in Group 4 medulloblastoma. We recently developed an inhibitor against Msi1 (luteolin) that disrupts it RNA binding properties. We showed that luteolin by itself and in combination with vincristine affected the growth of CHLA-01R cells. These findings suggest a combined therapeutic strategy (Msi1 + cell cycle/division inhibitors) to treat groups 4 medulloblastoma.